Kiniksa Pharmaceuticals Files 8-K on Financials

Ticker: KNSA · Form: 8-K · Filed: Apr 29, 2025 · CIK: 1730430

Kiniksa Pharmaceuticals International, PLC 8-K Filing Summary
FieldDetail
CompanyKiniksa Pharmaceuticals International, PLC (KNSA)
Form Type8-K
Filed DateApr 29, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Kiniksa Pharma dropped an 8-K detailing their financial results and condition as of April 29, 2025.

AI Summary

Kiniksa Pharmaceuticals International, plc filed an 8-K on April 29, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in England and Wales and its principal executive offices are located in London.

Why It Matters

This 8-K filing provides investors with crucial updates on Kiniksa Pharmaceuticals' financial performance and condition, which can influence investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant changes.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported is dated April 29, 2025.

Where is Kiniksa Pharmaceuticals International, plc incorporated?

The company is incorporated in England and Wales.

What is the business address of Kiniksa Pharmaceuticals International, plc?

The address of principal executive offices is 23 Old Bond Street, Floor 3, London, W1S 4PZ, England, United Kingdom.

What is the SEC file number for this filing?

The SEC file number is 001-38492.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2025 regarding Kiniksa Pharmaceuticals International, plc (KNSA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing